

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

X



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)
[Back](#)

[About MSK](#) [Cancer & Treatment](#)
[Bladder Cancer](#) [Learn About Cancer & Treatment](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA

MSK tests new treatments for bladder cancer. Treatment trials test new drugs, drug combinations, devices, and ways of doing procedures, surgery, or radiation therapy.

Sometimes a clinical trial gives you access to new therapies that are not yet available at most hospitals. Talk with your doctor about whether joining a clinical trial is right for you.

Clinical trials are designed to answer questions about:

- Safety
- Benefits
- Side effects
- Whether some people are helped more than others

MSK will start a clinical trial only if our researchers think we can improve methods for cancer:

- Prevention
- Treatment
- Diagnosis
- Screening

For more information, please read [Clinical Trials at MSK: What You Need to Know](#).

MSK is developing or improving treatments for people with bladder cancer.

- We led the way in developing [immunotherapy drugs for advanced bladder cancer](#).
- Our patients were among the first to get atezolizumab (Tecentriq®) as part of a clinical trial. Based on this research, it became the first new drug approved for bladder cancer in more than 20 years.
- Our researchers also directed studies that led to the approval of pembrolizumab (Keytruda®) for bladder cancer.

Current bladder cancer research at MSK

Our current research focuses on genetics and people with bladder cancer. We're looking at who is more likely to respond well to these immunotherapy drugs, based on the genetic makeup of their tumors.

We're always looking for ways to make these immunotherapy drugs work better in more people. That includes combining a checkpoint inhibitor with

chemotherapy, and testing combinations of checkpoint inhibitors.

MSK researchers also are exploring ways to improve responses to bladder cancer treatments other than immunotherapy.

Our experts can help determine which clinical trial is right for you, including some of our newly opened clinical trials:

- [21-166 A Phase II Study of Oral Erdafitinib in People with Recurrent Non-Invasive Bladder Cancer](#)
- [21-314 A Phase I Study of 2141-V11 Immunotherapy in People with Non-Muscle Invasive Bladder Cancer that Did Not Respond to Standard Treatment](#)
- [19-374 A Phase I/II Study Assessing the Addition of Gemcitabine to BCG Treatment in People with High-Grade Non-Muscle Invasive Bladder Cancer that Returned after Prior BCG](#)
- [17-602 A Phase II Study of Pembrolizumab Immunotherapy as Initial Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer](#)
- [18-460 A Phase II Study of Chemotherapy without Surgery in Patients with Muscle-Invasive Bladder Cancer and Certain Gene Mutations](#)

You can see a current listing of MSK's clinical trials for bladder cancer below.

Search by keywords:

and/or

Trial phase:

Search

21 Clinical Trials found

[A Phase 1 Study of DS-2243a in People With Advanced Solid Tumors](#)

- Diseases: [Bladder Cancer](#) , [Sarcomas: Soft Tissue Sarcoma](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [Sandra P. D'Angelo](#)

[A Phase 1-2 Study of Nadofaragene Firadenovec in People With Low-Grade Upper Tract Urothelial Cancer](#)

- Diseases: [Bladder Cancer](#) , [Kidney Cancer](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

[A Phase 1/2 Study of Combination Drug Treatments for People With Urothelial Carcinoma](#)

- Diseases: [Bladder Cancer](#) , [Kidney Cancer](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) ,

[Who Can Join](#)

 [Samuel A. Funt](#)

[A Phase 1/2 Study of VLS-1488 in People With Various Types of Cancer](#)

- Diseases: [Bladder Cancer](#) , [Colorectal Cancer: Colon Cancer](#) , [Colorectal Cancer: Rectal Cancer](#) , [Head & Neck Cancer](#) , [Lung Cancer, Non-Small Cell: Other](#) , [Ovarian Cancer](#) , [Solid Tumors](#) , [Squamous Cell Carcinoma](#) , [Upper Gastrointestinal: Esophageal Cancer](#) , [Upper Gastrointestinal: Gastric Cancer](#) , [Uterine Sarcoma: Carcinosarcoma](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [Chrisann Kyi](#)

[A Phase 1a Study of AVA6000 in People with Solid Tumors](#)

- Diseases: [Bladder Cancer](#) , [Breast Cancer](#) , [Colorectal Cancer: Colon Cancer](#) , [Colorectal Cancer: Rectal Cancer](#) , [Head & Neck Cancer](#) , [Hepatobiliary](#) , [Hepatobiliary: Pancreatic Cancer](#) , [Lung Cancer, Non-Small Cell](#) , [Ovarian Cancer](#) , [Prostate Cancer: Metastatic Disease after Hormone-Reducing Therapy](#) , [Sarcomas](#) , [Solid Tumors](#) , [Upper Gastrointestinal: Esophageal Cancer](#) , [Upper Gastrointestinal: Pancreatic Cancer](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [William D. Tap](#)

[A Phase 1a Study of LY4101174 in People With Bladder or Prostate Cancer](#)

- Diseases: [Bladder Cancer](#) , [Prostate Cancer: Metastatic Disease after Hormone-Reducing Therapy](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [Jonathan E. Rosenberg](#)

[A Phase 1B/2 Study of ACR-368 Alone and with Gemcitabine in People with Ovarian, Endometrial, or Urothelial Cancer](#)

- Diseases: [Bladder Cancer](#) , [Ovarian Cancer](#) , [Uterine \(Endometrial\) Cancer](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [Chrisann Kyi](#)

[A Phase 2 Study of Autogene Cevumeran Plus Nivolumab Immunotherapy Versus Nivolumab Alone in People With Muscle-Invasive Bladder Cancer](#)

- Diseases: [Bladder Cancer](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [David H. Aggen](#)

[A Phase 2 Study of Datopotamab Deruxtecan Alone or With Other Anti-Cancer Drugs in People Endometrial, Ovarian, and Urothelial Cancers](#)

- Diseases: [Bladder Cancer](#) , [Ovarian Cancer](#) , [Uterine \(Endometrial\) Cancer](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [Vicky Makker](#)

[A Phase 2 Study of Disitamab Vedotin Alone and with Pembrolizumab Immunotherapy in People with Inoperable or Metastatic Urothelial Cancer](#)

- Diseases: [Bladder Cancer](#)
- Locations: [New York City](#) , [Commack Nonna's Garden Foundation Center](#) , [Basking Ridge](#) , [Westchester](#) , [Monmouth](#) , [Bergen](#) , [Nassau](#)

[Who Can Join](#)

 [Gopa Iyer](#)

[Load More](#)

© 2026 Memorial Sloan Kettering Cancer Center